Androgen-deprivation therapy (ADT) with docetaxel may improve quality of life (QoL) at 12 months among patients with metastatic hormone-sensitive prostate cancer
Dr. Mary-Ellen Taplin, Dana-Farber Cancer Institute, will review recent FDA approved treatment options and the clinical trials that were responsible for these important breakthroughs.
FDA approved abiraterone acetate tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate.
African American participation in prostate cancer clinical trials must move from 3-5% range to 10-12% range to determine the effectiveness of new treatments.
The U.S. Food and Drug Administration (FDA) approved apalutamide for the treatment of non-metastatic castration-resistant prostate cancer
Clinical trials have found that Enzalutamide and Apalutamide are both able to significantly delay prostate cancer progression in men with non-metastatic castration-resistant prostate cancer.